NasdaqGS:REGNBiotechs
WHO Ebola Trial Puts Regeneron’s Maftivimab Platform In Investor Focus
World Health Organization recommends Regeneron’s maftivimab for priority evaluation in clinical trials for the current Bundibugyo ebolavirus outbreak.
Maftivimab is a component of Inmazeb, which is already approved for Zaire ebolavirus treatment.
The recommendation positions Regeneron Pharmaceuticals (NasdaqGS:REGN) within an active emergency response affecting multiple African countries.
Regeneron Pharmaceuticals, traded as NasdaqGS:REGN, is widely known for its antibody platforms and...